The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: A novel mechanism of human disease

JAMA

Volumn 293, Issue 13, 2005, Pages 1653-1662

  Rother, Russell P ^a   Bell, Leonard ^a   Hillmen, Peter ^b   Gladwin, Mark T ^c,d  

^a ALEXION PHARMACEUTICALS   (United States)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; HEMOGLOBIN; NITRIC OXIDE;

ANEMIA; BLOOD CLOTTING DISORDER; CARDIOVASCULAR DISEASE; DYSTONIA; ERYTHROCYTE MEMBRANE; GASTROINTESTINAL DISEASE; HEMOGLOBIN DETERMINATION; HEMOGLOBINURIA; HOMEOSTASIS; HUMAN; IATROGENIC DISEASE; INTRAVASCULAR HEMOLYSIS; LUNG DISEASE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SICKLE CELL ANEMIA; SMOOTH MUSCLE RELAXATION; STRESS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; UROGENITAL TRACT DISEASE; VASOMOTOR REFLEX; GENERAL ASPECTS OF DISEASE; HEMOLYSIS; PHYSIOLOGY;

DISEASE; HEMOGLOBINS; HEMOLYSIS; HUMANS; NITRIC OXIDE;

EID: 15944398355     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.293.13.1653     Document Type: Review

References (127)

1. Hausladen A, Gow AJ, Stamler JS. Nitrosative stress: metabolic pathway involving the flavohemoglobin. Proc Natl Acad Sci U S A. 1998;95:14100-14105.
2. Crawford MJ, Goldberg DE. Role for the Salmonella flavohemoglobin in protection from nitric oxide. J Biol Chem. 1998;273:12543-12547.
3. Gardner PR, Gardner AM, Martin LA, Salzman AL. Nitric oxide dioxygenase: an enzymic function for flavohemoglobin. Proc Natl Acad Sci U S A. 1998;95: 10378-10383.
4. Minning DM, Gow AJ, Bonaventura J, et al. Ascaris haemoglobin is a nitric oxide-activated "deoxygenase." Nature. 1999;401:497-502.
5. Schechter AN, Gladwin MT. Hemoglobin and the paracrine and endocrine functions of nitric oxide. J Engl J Med. 2003;348:1483-1485.
6. Olson JS, Foley EW, Rogge C, Tsai AL, Doyle MP, Lemon DD. NO scavenging and the hypertensive effect of hemoglobin-based blood substitutes. Free Radic Biol Med. 2004;36:685-697.
7. Coin JT, Olson JS. The rate of oxygen uptake by human red blood cells. J Biol Chem. 1979;254:1178-1190.
8. Liu X, Miller MJ, Joshi MS, Sadowska-Krowicka H, Clark DA, Lancaster JR Jr. Diffusion-limited reaction of free nitric oxide with erythrocytes. J Biol Chem. 1998;273:18709-18713.
9. Liao JC, Hein TW, Vaughn MW, Huang KT, Kuo L. Intravascular flow decreases erythrocyte consumption of nitric oxide. Proc Natl Acad Sci U S A. 1999;96: 8757-8761.
10. Tabbara IA. Hemolytic anemias: diagnosis and management. Med Clin North Am. 1992;76:649-668.
11. Savitsky JP, Doczi J, Black J, Arnold JD. A clinical safety trial of stroma-free hemoglobin. Clin Pharmacol Ther. 1978;23:73-80.
12. Carmichael FJ, Ali AC, Campbell JA, et al. A phase I study of oxidized raffinose cross-linked human hemoglobin. Crit Care Med. 2000;28:2283-2292.
13. Lamy ML, Daily EK, Brinchant JF, et al. Randomized trial of diaspirin cross-linked hemoglobin solution as an alternative to blood transfusion after cardiac surgery. The DCLHb Cardiac Surgery Trial Collaborative Group. Anesthesiology. 2000;92; 646-656.
14. Viele MK, Weiskopf RB, Fisher D. Recombinant human hemoglobin does not affect renal function in humans: analysis of safety and pharmacokinetics. Anesthesiology. 1997;86:848-858.
15. Saxena R, Wijnhoud AD, Carton H, et al. Controlled safety study of a hemoglobin-based oxygen earner, DCLHb, in acute ischemic stroke. Stroke. 1999;30: 993-996.
16. Murray JA, Ledlow A, Launspach J, Evans D, Loveday M, Conklin JL. The effects of recombinant human hemoglobin on esophageal motor functions in humans. Gastroenterology. 1995;109:1241-1248.
17. Przybelski RJ, Daily EK, Kisicki JC, Mattia-Goldberg C, Bounds MJ, Colburn WA. Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution. Crit Care Med. 1996; 24:1993-2000.
18. Lamuraglia GM, O'Hara PJ, Baker WH, et al. The reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin-based solution. J Vasc Surg. 2000;31:299-308.
19. Erhart SM, Cole DJ, Patel PM, Drummond JC, Burhop KE. Effect of alpha-alpha diaspirin crosslinked hemoglobin (DCLHb) on the potency of sodium nitroprusside and nitroglycerine to decrease blood pressure in rats: a dose-response study. Artif Cells Blood Substit Immobil Biotechnol. 2000;28:385-396.
20. Deem S, Kim JU, Manjula BN, et al. Effects of S-nitrosation and cross-linking of hemoglobin on hypoxic pulmonary vasoconstriction in isolated rat lungs. Circ Res. 2002;91:626-632.
21. Cannon RO III, Schlechter AN, Panza JA, et al. Effects of inhaled nitric oxide on regional blood flow are consistent with intravascular nitric oxide delivery. J Clin Invest. 2001;108:279-287.
22. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350: 886-895.
23. Moyo VM, Mukhina GL, Garrett ES, Brodsky RA. Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. Br J Haematol. 2004;126:133-138.
24. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 1987;2:1057-1058.
25. Olsen SB, Tang DB, Jackson MR, Gomez ER, Ayala B, Alving BM. Enhancement of platelet deposition by cross-linked hemoglobin in a rat carotid endarterectomy model. Circulation. 1996;93:327-332.
26. Schafer A, Wiesmann F, Neubauer S, Eigenthaler M, Bauersachs J, Channon KM. Rapid regulation of platelet activation in vivo by nitric oxide. Circulation. 2004;109:1819-1822.
27. Wagener FA, Eggert A, Boerman OC, et al. Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. Blood. 2001;98:1802-1811.
28. Nagel RL, Gibson QH. The binding of hemoglobin to haptoglobin and its relation to subunit dissociation of hemoglobin. J Biol Chem. 1971;246:69-73.
29. Kristiansen M, Graversen JH, Jacobsen C, et al. Identification of the haemoglobin scavenger receptor. Nature. 2001;409:198-201.
30. Jison ML, Munson PJ, Barb JJ, et al. Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. Blood. 2004;104:270-280.
31. Otterbein LE, Zuckerbraun BS, Haga M, et al. Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury. Nat Med. 2003;9:183-190.
32. Prestera T, Talalay P, Alam J, Ahn YI, Lee PJ, Choi AM. Parallel induction of heme oxygenase-1 and chemoprotective phase 2 enzymes by electrophiles and antioxidants: regulation by upstream antioxidant-responsive elements (ARE). Mol Med. 1995;1:827-837.
33. Ryter SW, Otterbein LE, Morse D, Choi AM. Heme oxygenase/carbon monoxide signaling pathways: regulation and functional significance. Mol Cell Biochem. 2002;234-235:249-263.
34. Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci U S A. 2002;99:16093-16098.
35. Sedlak TW, Snyder SH. Bilirubin benefits: cellular protection by a biliverdin reductase antioxidant cycle. Pediatrics. 2004;113:1776-1782.
36. Sears DA. Disposal of plasma heme in normal man and patients with intravascular hemolysis. J Clin Invest. 1970;49:5-14.
37. Philippidis P, Mason JC, Evans BJ, et al. Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: antiinflammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res. 2004;94:119-126.
38. Nakai K, Ohta T, Sakuma I, et al. Inhibition of endothelium-dependent relaxation by hemoglobin in rabbit aortic strips: comparison between acellular hemoglobin derivatives and cellular hemoglobins. J Cardiovasc Pharmacol. 1996;28:115-123.
39. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8:1383-1389.
40. Gladwin MT, Lancaster JR, Freeman BA, Schlechter AN. Nitric oxide's reactions with hemoglobin: a view through the SNO-storm. Nat Med. 2003;9:496-500.
41. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem. 1996;42:1589-1600.
42. Hartmann RC, Jenkins DE Jr, McKee LC, Heyssel RM. Paroxysmal nocturnal hemoglobinuria: clinical and laboratory studies relating to iron metabolism and therapy with androgen and iron. Medicine. 1966;45: 331-363.
43. Naumann HN, Diggs LW, Barreras L, Williams BJ. Plasma hemoglobin and hemoglobin fractions in sickle cell crisis. Am J Clin Pathol. 1971;56:137-147.
44. Pohl U, Lamontagne D. Impaired tissue perfusion after inhibition of endothelium-derived nitric oxide. Basic Res Cardiol. 1991;86(suppl 2):97-105.
45. Eberhardt RT, McMahon L, Duffy SJ, et al. Sickle cell anemia is associated with reduced nitric oxide bioactivity in peripheral conduit and resistance vessels. Am J Hematol. 2003;74:104-111.
46. Nath KA, Shah V, Haggard JJ, et al. Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease. Am J Physiol Regul Integr Comp Physiol. 2000;279:R1949-R1955.
47. Kaul DK, Liu XD, Fabry ME, Nagel RL. Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse. Am J Physiol Heart Circ Physiol. 2000; 278:H1799-H1806.
48. Kaul DK, Liu XD, Chang HY, Nagel RL, Fabry ME. Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. J Clin Invest. 2004;114:1136-1145.
49. Gladwin MT, Schechter AN, Ognibene FP, et al. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation. 2003;107:271-278.
50. Schnog JJ, Jager EH, van der Dijs FP, et al. Evidence for a metabolic shift of arginine metabolism in sickle cell disease. Ann Hematol. 2004;83:371-375.
51. Morris CR, Morris SM Jr, Hagar W, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med. 2003;168:63-69.
52. Azizi E, Dror Y, Wallis K. Arginase activity in erythrocytes of healthy and ill children. Clin Chim Acta. 1970;28:391-396.
53. Hess JR, MacDonald VW, Brinkley VW. Systemic and pulmonary hypertension after resuscitation with cell-free hemoglobin. J Appl Physiol. 1993; 74:1769-1778.
54. Lee R, Neya K, Svizzero TA, Vlahakes GJ. Limitations of the efficacy of hemoglobin-based oxygen-carrying solutions. J Appl Physiol. 1995;79:236-242.
55. de Figueiredo LF, Mathru M, Solanki D, MacDonald VW, Hess J, Kramer GC. Pulmonary hypertension and systemic vasoconstriction may offset the benefits of acellular hemoglobin blood substitutes. J Trauma. 1997;42:847-854.
56. Vogel WM, Dennis RC, Cassidy G, Apstein CS, Valeri CR. Coronary constrictor effect of stroma-free hemoglobin solutions. Am J Physiol. 1986;251:H413-H420.
57. Ulatowski JA, Nishikawa T, Matheson-Urbaitis B, Bucci E, Traystman RJ, Koehler RC. Regional blood flow alterations after bovine fumaryl beta beta-crosslinked hemoglobin transfusion and nitric oxide synthase inhibition. Crit Care Med. 1996;24:558-565.
58. Sloan EP, Koenigsberg M, Gens D, et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA. 1999;282: 1857-1864.
59. Clark DA, Butler SA, Braren V, Hartmann RC, Jenkins DE Jr. The kidneys in paroxysmal nocturnal hemoglobinuria. Blood. 1981;57:83-89.
60. Rosse WF. Paroxysmal nocturnal hemoglobinuria. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al. Hematology: Basic Principles and Practice. 3rd ed. New York, NY: Churchill Livingstone; 2000:331-342.
61. Gault MH, Duffett S, Purchase L, Murphy J. Hemodialysis intravascular hemolysis and kinked blood lines. Nephron. 1992;62:267-271.
62. Hirsch DP, Holloway RH, Tytgat GN, Boeckxstaens GE. Involvement of nitric oxide in human transient lower esophageal sphincter relaxations and esophageal primary peristalsis. Gastroenterology. 1998;115: 1374-1380.
63. Eherer AJ, Schweiz I, Hammer HF, et al. Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. Gut. 2002;50:758-764.
64. Bortolotti M, Pandolfo N, Giovannini M, Mari C, Miglioli M. Effect of sildenafil on hypertensive lower oesophageal sphincter. Eur J Clin Invest. 2002;32:682-685.
65. Norris SL, Johnson C, Haywood LJ. Left ventricular filling pressure in sickle cell anemia. J Assoc Acad Minor Phys. 1992;3:20-23.
66. Sutton LL, Castro O, Cross DJ, Spencer JE, Lewis JF. Pulmonary hypertension in sickle cell disease. Am J Cardiol. 1994;74:626-628.
67. Adedeji MO, Cespedes J, Allen K, Subramony C, Hughson MD. Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med. 2001;125:1436-1441.
68. Castro O, Hoque M, Brown BD. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood. 2003;101: 1257-1261.
69. Vichinsky EP. Pulmonary hypertension in sickle cell disease. N Engl J Med. 2004;350:857-859.
70. Grisaru D, Rachmilewitz EA, Mosseri M, et al. Cardiopulmonary assessment in beta-thalassemia major. Chest. 1990;98:1138-1142.
71. Du ZD, Roguin N, Milgram E, Saab K, Koren A. Pulmonary hypertension in patients with thalassemia major. Am Heart J. 1997;134:532-537.
72. Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood. 2001;97:3411-3416.
73. Zakynthinos E, Vassilakopoulos T, Kaltsas P, et al. Pulmonary hypertension, interstitial lung fibrosis, and lung iron deposition in thalassaemia major. Thorax. 2001;56:737-739.
74. Hahalis G, Manolis AS, Apostolopoulos D, Alexopoulos D, Vagenakis AG, Zoumbos NC. Right ventricular cardiomyopathy in beta-thalassaemia major. Eur Heart J. 2002;23:147-156.
75. Littera R, La Nasa G, Derchi G, Cappellini MD, Chang CY, Contu L. Long-term treatment with sildenafil in a thalassemic patient with pulmonary hypertension. Blood. 2002;100:1516-1517.
76. Atichartakarn V, Likittanasombat K, Chuncharunee S, et al. Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders. Int J Hematol. 2003;78:139-145.
77. Uchida T, Miyake T, Matsuno M, et al. Fatal pulmonary thromboembolism in a patient with paroxysmal nocturnal hemoglobinuria. Rinsho Ketsueki. 1998; 39:150-152.
78. Heller PG, Grinberg AR, Lencioni M, Molina MM, Roncoroni AJ. Pulmonary hypertension in paroxysmal nocturnal hemoglobinuria. Chest. 1992;102:642-643.
79. Stewart GW, Amess JA, Eber SW, et al. Thromboembolic disease after splenectomy for hereditary stomatocytosis. Br J Haematol. 1996;93:303-310.
80. Verresen D, De Backer W, Van Meerbeeck J, Neetens I, Van Marck E, Vermeire P. Spherocytosis and pulmonary hypertension coincidental occurrence or causal relationship? Eur Respir J. 1991;4:629-631.
81. Hayag-Barin JE, Smith RE, Tucker FC Jr. Hereditary spherocytosis, thrombocytosis, and chronic pulmonary emboli: a case report and review of the literature. Am J Hematol. 1998;57:82-84.
82. Murali B, Drain A, Seller D, Dunning J, Vuylsteke A. Pulmonary thromboendarterectomy in a case of hereditary stomatocytosis. Br J Anaesth. 2003;91:739-741.
83. Jardine DL, Laing AD. Delayed pulmonary hypertension following splenectomy for congenital spherocytosis. Intern Med J. 2004;34:214-216.
84. Jais X, Till SJ, Cynober T, et al. An extreme consequence of splenectomy in dehydrated hereditary stomatocytosis: gradual thrombo-embolic pulmonary hypertension and lung-heart transplantation. Hemoglobin. 2003;27:139-147.
85. Stuard ID, Heusinkveld RS, Moss AJ. Microangiopathic hemolytic anemia and thrombocytopenia in primary pulmonary hypertension. N Engl J Med. 1972; 287:869-870.
86. McCarthy JT, Staats BA. Pulmonary hypertension, hemolytic anemia, and renal failure: a mitomycin-associated syndrome. Chest. 1986;89:608-611.
87. Jubelirer SJ. Primary pulmonary hypertension: its association with microangiopathic hemolytic anemia and thrombocytopenia. Arch Intern Med. 1991;151: 1221-1223.
88. Geissler RG, Ganser A, Hubner K, Hor G, Hoelzer D. 47-year-old patient with pulmonary hypertension, anemia and thrombocytopenia. Internist (Berl). 1995;36:385-388.
89. Suzuki H, Nakasato M, Sato S, et al. Microangiopathic hemolytic anemia and thrombocytopenia in a child with atrial septal defect and pulmonary hypertension. Tohoku J Exp Med. 1997;181:379-384.
90. Labrune P, Zittoun J, Duvaltier I, et al. Haemolytic uraemic syndrome and pulmonary hypertension in a patient with methionine synthase deficiency. Eur J Pediatr. 1999;158:734-739.
91. Fischer EG, Marek JM, Morris A, Nashelsky MB. Cholesterol granulomas of the lungs associated with microangiopathic hemolytic anemia and thrombocytopenia in pulmonary hypertension. Arch Pathol Lab Med. 2000;124:1813-1815.
92. Chou R, DeLoughery TG. Recurrent thromboembolic disease following splenectomy for pyruvate kinase deficiency. Am J Hematol. 2001;67:197-199.
93. Hebbel RP. Auto-oxidation and a membrane-associated "Fenton reagent": a possible explanation for development of membrane lesions in sickle erythrocytes. Clin Haematol. 1985;14:129-140.
94. Sadrzadeh SM, Graf E, Panter SS, Hallaway PE, Eaton JW. Hemoglobin: a biologic fenton reagent. J Biol Chem. 1984;259:14354-14356.
95. Manci EA, Culberson DE, Yang YM, et al. Causes of death in sickle cell disease: an autopsy study. Br J Haematol. 2003;123:359-365.
96. Jison ML, Gladwin MT. Hemolytic anemia-associated pulmonary hypertension of sickle cell disease and the nitric oxide/arginine pathway. Am J Respir Crit Care Med. 2003;168:3-4.
97. Simionatto CS, Cabal R, Jones RL, Galbraith RA. Thrombophlebitis and disturbed hemostasis following administration of intravenous hematin in normal volunteers. Am J Med. 1988;85:538-540.
98. Studt JD, Hovinga JA, Antoine G, et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood. 2005;105: 542-544.
99. Radomski MW, Palmer RM, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol. 1987;92:639-646.
100. Megson IL, Sogo N, Mazzei FA, Butler AR, Walton JC, Webb DJ. Inhibition of human platelet aggregation by a novel S-nitrosothiol is abolished by haemoglobin and red blood cells in vitro: implications for anti-thrombotic therapy. Br J Pharmacol. 2000;131: 1391-1398.
101. Broekman MJ, Eiroa AM, Marcus AJ. Inhibition of human platelet reactivity by endothelium-derived relaxing factor from human umbilical vein endothelial cells in suspension: blockade of aggregation and secretion by an aspirin-insensitive mechanism. Blood. 1991;78:1033-1040.
102. Catani MV, Bernassola F, Rossi A, Melino G. Inhibition of clotting factor XIII activity by nitric oxide. Biochem Biophys Res Commun. 1998;249:275-278.
103. Shao J, Miyata T, Yamada K, et al. Protective role of nitric oxide in a model of thrombotic microangiopathyin rats. J Am Soc Nephrol. 2001;12:2088-2097.
104. Kayanoki Y, Kawata S, Yamasaki E, et al. Reduced nitric oxide production by L-arginine deficiency in lysinuric protein intolerance exacerbates intravascular coagulation. Metabolism. 1999;48:1136-1140.
105. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol. 1998;159:2164-2171.
106. Corbin JD, Francis SH, Webb DJ. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology. 2002;60:4-11.
107. Graca-Souza AV, Arruda MA, de Freitas MS, Barja-Fidalgo C, Oliveira PL. Neutrophil activation by heme: implications for inflammatory processes. Blood. 2002;99:4160-4165.
108. Wagener FA, Feldman E, de Witte T, Abraham NG. Heme induces the expression of adhesion molecules ICAM-1, VCAM-1, and E selectin in vascular endothelial cells. Proc Soc Exp Biol Med. 1997;216: 456-463.
109. Bignold LP. Importance of platelets in increased vascular permeability evoked by experimental haemarthrosis in synovium of the rat. Pathology. 1980;12:169-179.
110. Xue M, Del Bigio MR. Intracerebral injection of autologous whole blood in rats: time course of inflammation and cell death. Neurosci Lett. 2000;283: 230-232.
111. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995;96:60-68.
112. Kannan MS, Guiang S, Johnson DE. Nitric oxide: biological role and clinical uses. Indian J Pediatr. 1998;65:333-345.
113. Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73:703-711.
114. Bessler M, Mason PJ, Hillmen P, et al. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J. 1994;13: 110-117.
115. Holguin MH, Fredrick LR, Bernshaw NJ, Wilcox LA, Parker CJ. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest. 1989;84: 7-17.
116. Van Lente F, Marchand A, Galen RS. Diagnosis of hemolytic disease by electrophoresis of erythrocyte lactate dehydrogenase isoenzymes on cellulose acetate or Agarose. Clin Chem. 1981;27:1453-1455.
117. Ravel R. Factor deficiency anemia. In: Clinical Laboratory Medicine: Clinical Applications of Laboratory Data. 6th ed. St Louis, Mo: Mosby-Year Book; 1995:29-30.
118. Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350:552-559.
119. Raquette RL, Yoshimura R, Veiseh C, Kunkel L, Gajewski J, Rosen PJ. Clinical characteristics predict response to antithymocyte globulin in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1997;96:92-97.
120. Ravel R. Depletion anemia. In: Clinical Laboratory Medicine: Clinical Applications of Laboratory Data. 6th ed. St Louis, Mo: Mosby-Year Book; 1995: 54.
121. Rubin H. Paroxysmal nocturnal hemoglobinuria with renal failure. JAMA. 1971;215:433-436.
122. Valla D, Dhumeaux D, Babany G, et al. Hepatic vein thrombosis in paroxysmal nocturnal hemoglobinuria: a spectrum from asymptomatic occlusion of hepatic venules to fatal Budd-Chiari syndrome. Gastroenterology. 1987;93:569-575.
123. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253-1258.
124. Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2003;102: 3587-3591.
125. Wiedmer T, Hall SE, Ortel TL, Kane WH, Rosse WF, Sims PJ. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood. 1993;82:1192-1196.
126. Sims PJ, Rollins SA, Wiedmer T. Regulatory control of complement on blood platelets: modulation of platelet procoagulant responses by a membrane inhibitor of the C5b-9 complex. J Biol Chem. 1989;264: 19228-19235.
127. Hill A, Elebute M, Marsh JC, et al. Sustained control of hemolysis and symptoms and reduced transfusion requirements over a period of 2 years in paroxysmal nocturnal hemoglobinuria (PNH) with eculizumab therapy. Blood. 2004;104:772a.